Outil d'établissement de liens dans le cadre de l'appel 2026 de l'ERDERA pour des essais cliniques
Aperçu
L'appel 2026 de l'ERDERA pour des essais cliniques (ECTC 2026) est dirigé par l'Alliance européenne de recherche sur les maladies rares (ERDERA), en partenariat avec l'Institut de génétique des IRSC. Cette possibilité de financement vise à soutenir des essais cliniques interventionnels multinationaux de phase I, de phase I/II et de phase II, conformes aux bonnes pratiques cliniques (BPC), dans le domaine des maladies rares. De plus amples renseignements sur l'ECTC 2026 sont disponibles sur le site Web d'ERDERA (en anglais seulement). Les renseignements à l'intention des chercheurs canadiens seront publiés à une date ultérieure dans RechercheNet des IRSC.
Pour atteindre les objectifs de l'ECTC 2026, il est essentiel d'établir de solides liens et collaborations entre les candidats au Canada et ceux des autres pays admissibles dans le cadre du programme de l'ERDERA. L'un des moyens par lesquels les IRSC soutiennent le développement de tels liens est cet outil d'établissement de liens, qui vise à faciliter la formation d'équipes de recherche internationales (consortia) et l'élaboration conjointe de demandes.
Avis
Important : Pour consigner des renseignements dans l'outil d'établissement de liens, veuillez remplir ce court formulaire. Vos renseignements seront ajoutés au tableau ci-dessous lors de la prochaine mise à jour. Veuillez noter que cette démarche n'est pas obligatoire.
Ce formulaire peut être rempli par des chercheurs ou investigateurs du Canada et des autres pays admissibles dans le cadre du programme de l'ERDERA qui souhaitent partager de l'information ou établir des collaborations dans le cadre de cette possibilité de financement.
L'information est publiée dans la langue dans laquelle elle a été soumise. Elle est donnée sur une base volontaire et ne procure aucun avantage particulier dans l'évaluation ou le financement des demandes.
Nous vous invitons à consulter le tableau ci-dessous et à communiquer avec les personnes ou groupes dont les intérêts correspondent aux vôtres afin de découvrir d'éventuelles synergies et possibilités de collaboration. Le tableau sera généralement mis à jour chaque semaine jusqu'en octobre 2027, puis régulièrement par la suite.
| Coordonnées | Expertise | Affections / domaines thérapeutiques | Types d'intervention | Population cible |
|---|---|---|---|---|
| Tamorah Lewis tamorah.lewis@sickkids.ca The Hospital for Sick Children Researcher, Practitioner/Physician Ontario Canada 416-813-2143 |
Neonatology and Pediatric Clinical Pharmacology - PK/PD studies, pharmacogenetics, drug toxicity, precision medicine | Neonatal disease, pediatric rare disease | Small molecules, medical devices | Fetus, neonate, children |
| Breanne Stewart breanne.stewart@micyrn.ca RareKids-CAN Director- Pediatric Rare Disease Clinical Trials and Treatment Network AB Canada |
Consultation services for the following areas: study design, outcomes, biostatistics, pharmacology, registry and natural history, real world data and evidence, patient and family engagement, knowledge translation/mobilization, equity diversity & inclusivity, Indigeneity, sex & gender, transition to adulthood/youth perspectives, validated database & data management, training & mentorship. Site & Investigator Identification across 16 pediatric research institutes & affiliated across Canada | Disease/condition agnostic (excluding oncology) | Any (open to all intervention types) | Fetuses, neonates, children, adolescents, young adults |
|
Aiman Siddiqi aiman.siddiqi@micyrn.ca Director of Clinical Research Maternal Infant Child and Youth Research Network (MICYRN) BC Canada |
Pre-funding services: Consultation, study design and protocol optimization, letters of support. Post funding: Protocol development, Health Canada regulatory submission, centralized ethics submission, bilingual monitoring, quality assurance, DSMB project management support, biostatistical design & analysis, knowledge translation & communications, patient & family engagement, administration, finance and governance of grants, database support. |
Any | Any (open to all interventions types) | Fetuses, neonates, children, adolescents, young adults |
|
Fausto Queda fqueda@vectorb2b.com VectorB2B (en anglais seulement) Senior Project Manager - CTMO Portugal |
Clinical development and trial management experience across infectious diseases, oncology, ophthalmology, medical devices, and biologics. Expertise includes observational studies, in vitro and in vivo efficacy studies, ADME and pharmacokinetic (PK) studies, feasibility assessments, regulatory submissions, and the implementation and coordination of multicentre national and international clinical trials ranging from Phase I to Phase III. Therapeutic areas include diabetic foot infections, ventilator-associated pneumonia, neurotrophic keratopathy, and spinal cord injury. | Any | To be determined | To be determined |
|
Hernan Gonorazky hernan.gonorazky@sickkids.ca Practitioner/Physician, Researcher The Hospital for Sick Children (SickKids) (en anglais seulement) Ontario Canada |
Methodological expertise: Precision medicine and advanced therapeutics clinical trials, including gene therapy, gene editing, antisense oligonucleotide (ASO) therapies, small molecules, and drug repurposing; clinical trial design, operations, and coordination; natural history studies and patient registries; clinical outcome assessment selection and validation; biomarker identification and development; and translational research in rare genetic disorders Clinical expertise: Genetics, neurology, neuromuscular disorders, neurodegenerative disorders, rare diseases |
Rare and ultra-rare paediatric neuromuscular and neurodegenerative disorders, such as muscular dystrophies (e.g. DMD, LGMD, MDC1A), spinal muscular atrophy (SMA), congenital myopathies (e.g. MTM, NM), inherited peripheral neuropathies (e.g. CMT), and lysosomal storage disorders with CNS involvement | Any (open to all intervention types) | Children and adolescents (birth to 18 years of age) with neuromuscular/neurodegenerative disorders |
| Robert Hamilton robert.hamilton@sickkids.ca Hospital for Sick Children (SickKids) Ontario Canada |
Biomarkers (including companion), mechanisms, precision medicine, registry, natural history and real world data for rare cardiac disorders affecting children and young adults, particularly inherited arrhythmia and arrhythmogenic cardiomyopathy syndromes. Acquired cardiac conduction disorders. | Arrhythmogenic Cardiomyopathy, Brugada syndrome, Catecholaminergic Polymorphic Ventricular Tachycardia, Calmodulinopathy, TECRL mutations, Triadin Knockout Syndrome. Acquired cardiac conduction disorders: Autoimmune Congenital Heart block, Chagas disease and Lyme disease | Any | Fetuses, neonates, children, adolescents, young adults |
| Jacob Jaya jacob.jaya@insilicotrials.com Strategic Partnerships InSilicoTrials Italy |
Methodological expertise: In silico clinical trial design and analysis for rare and pediatric populations, including virtual patients, digital twins, synthetic control arms, MIDD, PK/PD and systems pharmacology modelling, cardiac safety assessment, and regulatory-grade evidence generation. Expertise also includes the use of natural history and real-world data to create external comparators. Clinical expertise: Applied modelling experience in cardiology, cardiac safety, metabolic and neuromuscular disorders, and rare pediatric diseases. We act as a methodological partner and collaborate with clinical experts for trial leadership and disease-specific input. |
Cardiovascular hypertrophic and other cardiomyopathies, inherited arrhythmia syndromes and channelopathies (e.g. long QT syndrome), and drug-induced proarrhythmia / cardiac safety. Broader interest and experience in paediatric and orphan rare genetic diseases, and openness to metabolic and neuromuscular conditions where quantitative modelling adds value. | Any (open to all intervention types) | Across the lifespan, with particular experience in paediatric populations (neonates, children, adolescents) and adults. |
- Date de modification :